Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.

Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ.

PLoS Negl Trop Dis. 2016 Aug 17;10(8):e0004926. doi: 10.1371/journal.pntd.0004926. eCollection 2016 Aug.

2.

Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure concept.

Rustomjee R, Lockhart S, Shea J, Fourie PB, Hindle Z, Steel G, Hussey G, Ginsberg A, Brennan MJ.

Tuberculosis (Edinb). 2014 Mar;94(2):178-82. doi: 10.1016/j.tube.2013.11.002. Epub 2013 Dec 8.

3.

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN.

Vaccine. 2006 Jan 12;24(2):116-23. Epub 2005 Aug 18.

PMID:
16140433
4.

The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.

Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN.

J Infect Dis. 2005 Aug 1;192(3):360-6. Epub 2005 Jun 30.

PMID:
15995948
5.

Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters.

Stratford R, McKelvie ND, Hughes NJ, Aldred E, Wiseman C, Curtis J, Bellaby T, Bentley M, Hindle Z, Brennan FR, Chatfield SN, Dougan G, Khan SA.

Infect Immun. 2005 Jan;73(1):362-8.

6.

Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

Khan SA, Stratford R, Wu T, Mckelvie N, Bellaby T, Hindle Z, Sinha KA, Eltze S, Mastroeni P, Pickard D, Dougan G, Chatfield SN, Brennan FR.

Vaccine. 2003 Jan 17;21(5-6):538-48.

PMID:
12531654
7.

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, Ghaem-Maghami M, Sexton A, Khan M, Brennan FR, Everest P, Wu T, Pickard D, Holden DW, Dougan G, Griffin GE, House D, Santangelo JD, Khan SA, Shea JE, Feldman RG, Lewis DJ.

Infect Immun. 2002 Jul;70(7):3457-67.

8.

The global posttranscriptional regulator RsmA modulates production of virulence determinants and N-acylhomoserine lactones in Pseudomonas aeruginosa.

Pessi G, Williams F, Hindle Z, Heurlier K, Holden MT, Cámara M, Haas D, Williams P.

J Bacteriol. 2001 Nov;183(22):6676-83. Erratum in: J Bacteriol 2002 Jan;184(1):335.

9.
11.

Cloning and expression in Escherichia coli of a Streptomyces coelicolor A3(2) argCJB gene cluster.

Hindle Z, Callis R, Dowden S, Rudd BA, Baumberg S.

Microbiology. 1994 Feb;140 ( Pt 2):311-20.

PMID:
8180696

Supplemental Content

Loading ...
Support Center